首页> 美国卫生研究院文献>BioMed Research International >Hp-β-CD-Voriconazole In Situ Gelling System for Ocular Drug Delivery: In Vitro, Stability, and Antifungal Activities Assessment
【2h】

Hp-β-CD-Voriconazole In Situ Gelling System for Ocular Drug Delivery: In Vitro, Stability, and Antifungal Activities Assessment

机译:Hp-β-CD-伏立康唑原位凝胶系统用于眼部药物递送:体外,稳定性和抗真菌活性评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The objective of the present study was to design ophthalmic delivery systems based on polymeric carriers that undergo sol-to-gel transition upon change in temperature or in the presence of cations so as to prolong the effect of HP-β-CD Voriconazole (VCZ) in situ gelling formulations. The in situ gelling formulations of Voriconazole were prepared by using pluronic F-127 (PF-127) or with combination of pluronic F-68 (PF-68) and sodium alginate by cold method technique. The prepared formulations were evaluated for their physical appearance, drug content, gelation temperature (T gel), in vitro permeation studies, rheological properties, mucoadhesion studies, antifungal studies, and stability studies. All batches of in situ formulations had satisfactory pH ranging from 6.8 to 7.4, drug content between 95% and 100%, showing uniform distribution of drug. As the concentration of each polymeric component was increased, that is, PF-68 and sodium alginate, there was a decrease in T gel with increase in viscosity and mucoadhesive strength. The in vitro drug release decreased with increase in polymeric concentrations. The stability data concluded that all formulations showed the low degradation and maximum shelf life of 2 years. The antifungal efficiency of the selected formulation against Candida albicans and Asperigillus fumigatus confirmed that designed formulation has prolonged effect and retained its properties against fungal infection.
机译:本研究的目的是设计基于聚合物载体的眼科给药系统,该聚合物载体在温度变化或存在阳离子的情况下会发生溶胶-凝胶转变,从而延长HP-β-CD伏立康唑(VCZ)的作用原位胶凝制剂。伏立康唑的原位胶凝制剂是通过使用普卢尼克F-127(PF-127)或普卢尼克F-68(PF-68)和藻酸钠的组合通过冷法技术制备的。评估所制备的制剂的物理外观,药物含量,胶凝温度(T凝胶),体外渗透研究,流变特性,粘膜粘附研究,抗真菌研究和稳定性研究。所有批次的原位制剂具有令人满意的pH,范围为6.8至7.4,药物含量在95%至100%之间,显示出药物的均匀分布。随着每种聚合物组分(即PF-68和海藻酸钠)浓度的增加,T凝胶随着粘度和粘膜粘附强度的增加而降低。体外药物释放随着聚合物浓度的增加而降低。稳定性数据得出结论,所有配方均显示出低降解和2年的最大保存期限。所选制剂对白色念珠菌和烟曲霉的抗真菌效力证实了所设计的制剂具有延长的作用并保留了其针对真菌感染的特性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号